GRANTS JULY 1, 2021 - JUNE 30, 2022
- Project/Pilot Project Leaders
Channappanavar, Rudragouda, Vaxxinity, Immunogenicity and Efficacy of Vaxxinity COVID Vaccines in Transgenic Mice, 08/2021- 07/2022, $63,000.
Channappanavar, Rudragouda, OrganiCell Inc, Antiviral and immunomodulatory role of exosomes during SARS-CoV-2 infection, 08/2021- 07/2022, $50,000.
Cheng, Yong, HR21-050, Oklahoma Center for the Advancement of Science and Technology, WNK4-mediated Exosome Biogenesis Inhibits Cystic Fibrosis Macrophage Death during Nontuberculous Mycobacterial Infection, 12/01/2021-11/31/2024, $83,566.
Cheng, Yong, Oklahoma Nathan Shock Center on Aging Pilot Project, Genome-wide DNA methylation analysis in aging mouse lung macrophages during Mycobacterium tuberculosis infection, 11/15/2021-05/31/2022, $19,600.
Feng, Yu, 2120688, NSF, Determining the Effect of Airway Deformation on Pulmonary Air-Particle Dynamics, 07/01/2021-06/31/2024, $249,959.
McCall, Laura-Isobel, Burroughs Wellcome, Role of spatial metabolic heterogeneity in disease tropism, 2021-2026, $500,000
Patrauchan, Marianna A., 1R15GM124670-01, NIH/NIGMS, “Calcium signaling controls Pseudomonas aeruginosa invasion and adaptation to the host intracellular environment”, 08/2021-07/2024, $426,823.
- Mentor/Core Directors
Liu, Lin, Oklahoma Center for Adult Stem Cell Research, An iPSC-derived Human Lung Tissue Model for Post-Acute Sequelae of SARS-CoV-2 infection, 01/01/2022-12/31/2022, $168,000.
- Center Investigator
Pan, Chongle, 1R01AT011618-01, NCCIH, Proteomic Stable Isotope Probing as a Novel Approach for Linking Prebiotics with Active Gut Microbiota, 08/15/21-05/31/26, $1,904,300.
Ramesh, Rajagopal, 1R01CA254192-01A1, NCI, Exosomes as carriers of cancer therapeutics, 09/14/21-08/31/22, $2,881,110.
Vitiello, Peter, 1R21EY033075-01, NEI, Redox-dependent signaling in hyperoxia-induced retinal vascular arrest, 09/30/21-07/31/23, $543,750.
Walters, Matthew S, Oklahoma Center for Adult Stem Cell Research, HEYL Function in Airway Epithelial Differentiation, Regeneration and Disease, 07/01/2021-06/30/2022, $140,797.
Pereira, Anne H., 1R41EY032437-01, NEI, Novel Ophthalmic Product for Corneal Infections and Injuries, 09/30/21-09/29/22, $256,580.